These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 27639586)

  • 1. More Time Is Taken to Administer Tissue Plasminogen Activator in Ischemic Stroke Patients with Earlier Presentations.
    Rossi KC; Liang JW; Wilson N; Tuhrim S; Dhamoon MS
    J Stroke Cerebrovasc Dis; 2017 Jan; 26(1):70-73. PubMed ID: 27639586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative.
    Fonarow GC; Zhao X; Smith EE; Saver JL; Reeves MJ; Bhatt DL; Xian Y; Hernandez AF; Peterson ED; Schwamm LH
    JAMA; 2014 Apr 23-30; 311(16):1632-40. PubMed ID: 24756513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at Get With The Guidelines-Stroke hospitals.
    Schwamm LH; Ali SF; Reeves MJ; Smith EE; Saver JL; Messe S; Bhatt DL; Grau-Sepulveda MV; Peterson ED; Fonarow GC
    Circ Cardiovasc Qual Outcomes; 2013 Sep; 6(5):543-9. PubMed ID: 24046398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous Tissue Plasminogen Activator for Wake-Up Stroke: A Propensity Score-Matched Analysis.
    Anaissie JE; Monlezun DJ; Siegler JE; Waring ED; Dowell LN; Samai AA; George AJ; Kimbrough T; Berthaud J; Martin-Schild S
    J Stroke Cerebrovasc Dis; 2016 Nov; 25(11):2603-2609. PubMed ID: 27476340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan.
    Kono S; Deguchi K; Morimoto N; Kurata T; Deguchi S; Yamashita T; Ikeda Y; Matsuura T; Narai H; Omori N; Manabe Y; Yunoki T; Takao Y; Kawata S; Kashihara K; Abe K
    J Stroke Cerebrovasc Dis; 2013 Apr; 22(3):190-6. PubMed ID: 21968092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emergency medical service hospital prenotification is associated with improved evaluation and treatment of acute ischemic stroke.
    Lin CB; Peterson ED; Smith EE; Saver JL; Liang L; Xian Y; Olson DM; Shah BR; Hernandez AF; Schwamm LH; Fonarow GC
    Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):514-22. PubMed ID: 22787065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of early arterial reocclusion after tissue plasminogen activator-induced recanalization in acute ischemic stroke.
    Rubiera M; Alvarez-Sabín J; Ribo M; Montaner J; Santamarina E; Arenillas JF; Huertas R; Delgado P; Purroy F; Molina CA
    Stroke; 2005 Jul; 36(7):1452-6. PubMed ID: 15947260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Large-Vessel Occlusion Stroke: Effect of Recanalization on Outcome Depends on the National Institutes of Health Stroke Scale Score.
    Skagen K; Skjelland M; Russell D; Jacobsen EA
    J Stroke Cerebrovasc Dis; 2015 Jul; 24(7):1532-9. PubMed ID: 25922156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perception Versus Actual Performance in Timely Tissue Plasminogen Activation Administration in the Management of Acute Ischemic Stroke.
    Lin CB; Cox M; Olson DM; Britz GW; Constable M; Fonarow GC; Schwamm L; Peterson ED; Shah BR
    J Am Heart Assoc; 2015 Jul; 4(7):. PubMed ID: 26201547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Barriers to the use of intravenous tissue plasminogen activator for in-hospital strokes.
    Bunch ME; Nunziato EC; Labovitz DL
    J Stroke Cerebrovasc Dis; 2012 Nov; 21(8):808-11. PubMed ID: 21640608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The totaled health risks in vascular events (THRIVE) score predicts ischemic stroke outcomes independent of thrombolytic therapy in the NINDS tPA trial.
    Kamel H; Patel N; Rao VA; Cullen SP; Faigeles BS; Smith WS; Flint AC
    J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):1111-6. PubMed ID: 23122722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous thrombolysis with neuroprotective therapy by edaravone for ischemic stroke patients older than 80 years of age.
    Kono S; Deguchi K; Morimoto N; Kurata T; Yamashita T; Ikeda Y; Narai H; Manabe Y; Takao Y; Kawada S; Kashihara K; Takehisa Y; Inoue S; Kiriyama H; Abe K
    J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):1175-83. PubMed ID: 23507462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients with Low National Institutes of Health Stroke Scale Scores Have Longer Door-to-Needle Times: Analysis of a Telestroke Network.
    Bhatt A; Lesko A; Lucas L; Kansara A; Baraban E
    J Stroke Cerebrovasc Dis; 2016 Sep; 25(9):2253-8. PubMed ID: 27266620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 24/7 Neurocritical Care Nurse Practitioner Coverage Reduced Door-to-Needle Time in Stroke Patients Treated with Tissue Plasminogen Activator.
    Moran JL; Nakagawa K; Asai SM; Koenig MA
    J Stroke Cerebrovasc Dis; 2016 May; 25(5):1148-1152. PubMed ID: 26907680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gender Differences in Exclusion Criteria for Recombinant Tissue-Type Plasminogen Activator.
    Fredwall M; Sternberg S; Blackhurst D; Lee A; Leacock R; Nathaniel TI
    J Stroke Cerebrovasc Dis; 2016 Nov; 25(11):2569-2574. PubMed ID: 27618196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclusion of ischemic stroke patients from intravenous tissue plasminogen activator treatment for mild symptoms should not be based on low National Institutes of Health Stroke Scale Scores.
    Wendt M; Tütüncü S; Fiebach JB; Scheitz JF; Audebert HJ; Nolte CH
    J Stroke Cerebrovasc Dis; 2013 May; 22(4):550-3. PubMed ID: 23433783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aphasia predicts unfavorable outcome in mild ischemic stroke patients and prompts thrombolytic treatment.
    Nesi M; Lucente G; Nencini P; Fancellu L; Inzitari D
    J Stroke Cerebrovasc Dis; 2014 Feb; 23(2):204-8. PubMed ID: 23352114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant tissue-type plasminogen activator plus eptifibatide versus recombinant tissue-type plasminogen activator alone in acute ischemic stroke: propensity score-matched post hoc analysis.
    Adeoye O; Sucharew H; Khoury J; Tomsick T; Khatri P; Palesch Y; Schmit PA; Pancioli AM; Broderick JP;
    Stroke; 2015 Feb; 46(2):461-4. PubMed ID: 25523054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue plasminogen activator overdose in acute ischemic stroke patients linked to poorer functional outcomes.
    Sahlas DJ; Gould L; Swartz RH; Mohammed N; McNicoll-Whiteman R; Naufal F; Oczkowski W
    J Stroke Cerebrovasc Dis; 2014 Jan; 23(1):155-9. PubMed ID: 23375748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does modern ischemic stroke therapy in a large community-based dedicated stroke center improve clinical outcomes? A two-year retrospective study.
    Berlet MH; Stambo GW; Kelley M; Van Epps K; Woeste T; Steffen D
    J Stroke Cerebrovasc Dis; 2014; 23(5):869-78. PubMed ID: 24011839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.